REGENERON PHARMACEUTICALS INC

NASDAQ: REGN (Regeneron Pharmaceuticals, Inc.)

Kemas kini terakhir: 3 hari lalu, 12:30PM

553.29

5.33 (0.97%)

  • 1H 0.97%
  • 5H 0.13%
  • 1B 8.55%
  • 6B -19.56%
  • Tahun Ke Tarikh -22.64%
  • 1T -47.98%
  • 5T -15.94%
Penutupan Terdahulu 547.96
Buka 550.06
Jumlah Dagangan 565,260
Purata Dagangan (3B) 1,307,293
Modal Pasaran 59,735,953,408
Harga / Pendapatan (P/E TTM) 14.06
Harga / Pendapatan (P/E Ke hadapan) 16.13
Harga / Jualan (P/S) 4.62
Harga / Buku (P/B) 2.10
Julat 52 Minggu
476.49 (-13%) — 1,211.20 (118%)
Tarikh Pendapatan 1 Aug 2025
Hasil Dividen (DY TTM) 0.32%
Margin Keuntungan 31.94%
Margin Operasi (TTM) 19.94%
EPS Cair (TTM) 39.34
Pertumbuhan Hasil Suku Tahunan (YOY) -3.70%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 12.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 9.20%
Nisbah Semasa (MRQ) 4.93
Aliran Tunai Operasi (OCF TTM) 3.95 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 2.08 B
Pulangan Atas Aset (ROA TTM) 6.91%
Pulangan Atas Ekuiti (ROE TTM) 15.96%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Regeneron Pharmaceuticals, Inc. Menurun Menurun

AISkor Stockmoo

0.8
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam NA
Volatiliti Harga 1.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
REGN 60 B 0.32% 14.06 2.10
ARGX 35 B - 34.18 6.24
BMRN 11 B - 21.68 1.92
ROIV 8 B - - 1.69
ALNY 42 B - - 355.74
INCY 13 B - 344.70 3.65

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Value
% Dimiliki oleh Orang Dalam 1.89%
% Dimiliki oleh Institusi 91.99%
1,259.001,259.001,082.001,082.00905.00905.00728.00728.00551.00551.00Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25Q3 '25Q3 '25
Julat 52 Minggu
476.49 (-13%) — 1,211.20 (118%)
Julat Harga Sasaran
580.00 (4%) — 943.00 (70%)
Tinggi 943.00 (RBC Capital, 70.44%) Beli
Median 754.00 (36.28%)
Rendah 580.00 (Wells Fargo, 4.83%) Pegang
Purata 738.23 (33.43%)
Jumlah 10 Beli, 3 Pegang
Harga Purata @ Panggilan 559.81
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
UBS 11 Jul 2025 584.00 (5.55%) Pegang 567.74
05 Jun 2025 560.00 (1.21%) Pegang 483.07
Morgan Stanley 10 Jul 2025 754.00 (36.28%) Beli 559.76
02 Jun 2025 755.00 (36.46%) Beli 490.81
JP Morgan 09 Jun 2025 800.00 (44.59%) Beli 517.60
BMO Capital 02 Jun 2025 600.00 (8.44%) Beli 490.81
30 Apr 2025 800.00 (44.59%) Beli 598.76
Citigroup 02 Jun 2025 650.00 (17.48%) Beli 490.81
14 May 2025 700.00 (26.52%) Beli 571.36
Wells Fargo 30 May 2025 580.00 (4.83%) Pegang 490.28
30 Apr 2025 700.00 (26.52%) Beli 598.76
RBC Capital 27 May 2025 943.00 (70.44%) Beli 603.26
30 Apr 2025 943.00 (70.44%) Beli 598.76
Guggenheim 01 May 2025 810.00 (46.40%) Beli 590.00
Baird 30 Apr 2025 587.00 (6.09%) Pegang 598.76
25 Apr 2025 652.00 (17.84%) Pegang 602.64
Goldman Sachs 30 Apr 2025 804.00 (45.31%) Beli 598.76
Truist Securities 30 Apr 2025 940.00 (69.89%) Beli 598.76
23 Apr 2025 975.00 (76.22%) Beli 587.85
Canaccord Genuity 22 Apr 2025 850.00 (53.63%) Beli 585.49
Cantor Fitzgerald 22 Apr 2025 695.00 (25.61%) Beli 585.49
Papar semua

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
07 Jul 2025 Pengumuman Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
02 Jul 2025 Pengumuman Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
26 Jun 2025 Pengumuman Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
24 Jun 2025 Pengumuman Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
20 Jun 2025 Pengumuman Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
15 Jun 2025 Pengumuman Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
07 Jun 2025 Pengumuman Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
02 Jun 2025 Pengumuman Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
02 Jun 2025 Pengumuman Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
31 May 2025 Pengumuman Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
30 May 2025 Pengumuman Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
22 May 2025 Pengumuman Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
19 May 2025 Pengumuman Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
19 May 2025 Pengumuman Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
16 May 2025 Pengumuman 75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
15 May 2025 Pengumuman Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
01 May 2025 Pengumuman Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
01 May 2025 Pengumuman Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
29 Apr 2025 Pengumuman Regeneron Reports First Quarter 2025 Financial and Operating Results
28 Apr 2025 Pengumuman Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
28 Apr 2025 Pengumuman EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease
22 Apr 2025 Pengumuman Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
22 Apr 2025 Pengumuman FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion
21 Apr 2025 Pengumuman Regeneron Announces Investor Conference Presentations
Papar semua
Hasil Dividen (DY TTM) 0.32%
Nisbah Pembayaran 2.24%
Jangkaan Pembayaran Dividen Seterusnya Mar 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
20 May 2025 - 06 Jun 2025 0.88 Tunai
20 Feb 2025 - 20 Mar 2025 0.88 Tunai

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.76 2 0.32
580.21580.21559.88559.88539.54539.54519.21519.21498.87498.87Jul 7Jul 7Jul 8Jul 8Jul 9Jul 9Jul 10Jul 10Jul 11Jul 11Jul 14Jul 14Jul 15Jul 15Jul 16Jul 16

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
5.0005.0000.0000.000-5.000-5.000-10.000-10.000-15.000-15.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda